MeSH term
Frequency | Condition_Probility | Aged | 6 | 0.0 |
English Abstract | 2 | 0.0 |
Female | 20 | 0.0 |
Humans | 52 | 0.0 |
Male | 24 | 0.0 |
Middle Aged | 10 | 0.0 |
Cells, Cultured | 8 | 0.0 |
DNA Repair | 3 | 0.0 |
*Mutation | 6 | 0.0 |
Research Support, Non-U.S. Gov't | 35 | 0.0 |
*Transcription Factors, TFII | 6 | 5.0 |
Transcription, Genetic | 4 | 0.0 |
Xeroderma Pigmentosum/genetics | 7 | 24.0 |
Animals | 7 | 0.0 |
DNA Damage/*genetics | 2 | 3.0 |
*DNA Helicases | 12 | 5.0 |
*DNA-Binding Proteins | 9 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
Hair/*abnormalities | 6 | 60.0 |
Mice | 6 | 0.0 |
Proteins/genetics | 4 | 0.0 |
Sulfur/*deficiency | 2 | 100.0 |
Syndrome | 4 | 0.0 |
*Transcription Factors | 9 | 0.0 |
Ultraviolet Rays/adverse effects | 3 | 4.0 |
Abnormalities, Multiple/*genetics | 3 | 0.0 |
DNA Repair/*genetics | 6 | 1.0 |
Hair Diseases/*genetics | 8 | 72.0 |
Ichthyosis/genetics | 2 | 33.0 |
Phenotype | 6 | 0.0 |
Photosensitivity Disorders/*genetics | 2 | 33.0 |
Transcription Factors/genetics | 3 | 0.0 |
Transcription, Genetic/genetics | 3 | 0.0 |
Ultraviolet Rays | 13 | 2.0 |
Cockayne Syndrome/genetics | 6 | 42.0 |
*DNA Repair | 13 | 1.0 |
Mutation | 3 | 0.0 |
*Transcription, Genetic | 3 | 0.0 |
Xeroderma Pigmentosum/*genetics | 6 | 10.0 |
Culture Media | 2 | 0.0 |
Time Factors | 4 | 0.0 |
Adult | 14 | 0.0 |
Cystine/analysis | 2 | 28.0 |
DNA Repair/genetics | 2 | 1.0 |
Hair Diseases/*diagnosis/genetics | 2 | 100.0 |
Microscopy, Electron, Scanning | 3 | 1.0 |
Microscopy, Polarization | 2 | 33.0 |
Pregnancy | 2 | 0.0 |
Cell Line | 5 | 0.0 |
Cell Survival/*radiation effects | 2 | 12.0 |
Fibroblasts/radiation effects | 4 | 14.0 |
Proteins/*genetics | 4 | 0.0 |
Xeroderma Pigmentosum/complications/*genetics | 2 | 66.0 |
Alleles | 2 | 0.0 |
Hair Diseases/*genetics/pathology | 2 | 28.0 |
Mice, Inbred C57BL | 2 | 0.0 |
*Point Mutation | 2 | 0.0 |
Proteins/genetics/physiology | 2 | 3.0 |
Skin/pathology/radiation effects | 2 | 40.0 |
Cell Line, Transformed | 2 | 0.0 |
Child | 8 | 0.0 |
Child, Preschool | 4 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
DNA-Binding Proteins/*genetics | 2 | 0.0 |
Transfection | 3 | 0.0 |
Cerebral Cortex/*physiology | 2 | 4.0 |
*Communication Aids for Disabled | 2 | 66.0 |
Electroencephalography/*methods | 2 | 10.0 |
Evoked Potentials/*physiology | 2 | 10.0 |
Reproducibility of Results | 3 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 7 | 0.0 |
Sensitivity and Specificity | 2 | 0.0 |
*User-Computer Interface | 3 | 25.0 |
Amino Acid Sequence | 2 | 0.0 |
Cloning, Molecular | 2 | 0.0 |
Molecular Sequence Data | 5 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Adolescent | 6 | 0.0 |
Italy | 3 | 0.0 |
Pedigree | 3 | 0.0 |
Disease Models, Animal | 2 | 0.0 |
Hair/abnormalities | 2 | 20.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Administration, Cutaneous | 3 | 3.0 |
Prostate-Specific Antigen/blood | 2 | 2.0 |
Base Sequence | 4 | 0.0 |
Pyrimidine Dimers/*metabolism | 2 | 11.0 |
Sequence Alignment | 2 | 0.0 |
Genetic Complementation Test | 2 | 0.0 |
Genes, Recessive | 2 | 0.0 |
Infant | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 3 | 0.0 |
*Ultraviolet Rays | 2 | 0.0 |
DNA Damage | 3 | 0.0 |
Xeroderma Pigmentosum/genetics/metabolism | 2 | 25.0 |
RNA/biosynthesis | 2 | 2.0 |
Heterozygote | 2 | 0.0 |
Comparative Study | 4 | 0.0 |
Tomography, Emission-Computed, Single-Photon | 2 | 3.0 |
Follow-Up Studies | 2 | 0.0 |